MGMT promoter methylation in 1p19q-intact gliomas
MGMT promoter methylation in 1p19q-intact gliomas
About this item
Full title
MGMT promoter methylation in 1p19q-intact gliomas
Author / Creator
Publisher
New York: Springer US
Journal title
Journal of neuro-oncology, 2024-01, Vol.166 (1), p.73-78
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Objective
Standard-of-care for 1p19q-intact anaplastic gliomas is defined by the international randomized phase III CATNON trial, which found an overall survival (OS) benefit for adjuvant temozolomide (TMZ) when added to radiotherapy. Paradoxically, TMZ did not appear to benefit patients with IDH-wildtype gliomas, regardless of
MGMT
promot...
Alternative Titles
Full title
MGMT promoter methylation in 1p19q-intact gliomas
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2904156061
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2904156061
Other Identifiers
ISSN
0167-594X
E-ISSN
1573-7373
DOI
10.1007/s11060-023-04515-z
